{
    "clinical_study": {
        "@rank": "52130", 
        "arm_group": [
            {
                "arm_group_label": "Lipo-AB", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Amphotericin B", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the safety and efficacy of liposomal amphotericin B and amphotericin B\n      deoxycholate with or without flucytosine followed by fluconazole for the treatment of\n      cryptococcal meningitis."
        }, 
        "brief_title": "Liposomal Amphotericin B for the Treatment of Cryptococcal Meningitis", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Cryptococcal Meningitis", 
        "condition_browse": {
            "mesh_term": [
                "Meningitis", 
                "Meningitis, Cryptococcal"
            ]
        }, 
        "detailed_description": {
            "textblock": "Subjects who meet all eligible requirements will be randomized into study group \uff08Lipo-AB\uff09or\n      control group\uff08Amphotericin B deoxycholate\uff09 in 2:1 ratio. Subjects will be treated with\n      induction therapy in study group or in control group with flucytosine for at least 14 days,\n      and followed by consolidation therapy for another 56 days after CSF sterilization."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Adults with age of at least 18 years.\n\n          2. Within 7 days prior to, or at the time of screening visit, patient with cryptococcus\n             meningitis, diagnosed by :\n\n               1. CSF India ink staining positive OR\n\n               2. CSF cryptococcal antigen test positive OR\n\n               3. CSF culture positive\n\n          3. Patient or his/her legally acceptable representative has signed the written informed\n             consent form.\n\n        Exclusion Criteria:\n\n          1. Patients have laboratory abnormalities within 3 days prior to screening visit :\n\n               1. ALT > 5x UNL,\n\n               2. AST > 5x UNL,\n\n               3. Creatinine > 2mg/dl\n\n          2. Patient is pregnant or lactating.\n\n          3. Patient participate other investigational drug trial within 1 month before entering\n             this study.\n\n          4. Patient has some indications that another systemic antifungal drug would be needed in\n             addition to assigned drugs in study.\n\n          5. Patient had contraindication of amphotericin B or azole.\n\n          6. Patient is not available for lumbar puncture.\n\n          7. Patient with life expectancy less than 5 days."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "84", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02136030", 
            "org_study_id": "TTYLA0701"
        }, 
        "intervention": [
            {
                "arm_group_label": "Lipo-AB", 
                "description": "4mg/kg/day, IV infusion", 
                "intervention_name": "Liposomal amphotericin B", 
                "intervention_type": "Drug", 
                "other_name": "Lipo-AB"
            }, 
            {
                "arm_group_label": "Amphotericin B", 
                "description": "1mg/kg/day, IV infusion", 
                "intervention_name": "Amphotericin B-deoxycholate", 
                "intervention_type": "Drug", 
                "other_name": "Amphotericin B"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Amphotericin B", 
                "Liposomal amphotericin B", 
                "Amphotericin B, deoxycholate drug combination", 
                "Deoxycholic Acid"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Cryptococcal meningitis", 
        "lastchanged_date": "May 8, 2014", 
        "link": {
            "description": "Clinical trials network in Taiwan", 
            "url": "http://www.google.com/search?q=emome&ie=utf-8&oe=utf-8"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Taipei", 
                    "country": "Taiwan", 
                    "zip": "100"
                }, 
                "name": "National Taiwan University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Study to Evaluate the Safety and Efficacy of Liposomal Amphotericin B and Amphotericin B Deoxycholate With or Without Flucytosine Followed by Fluconazole, for the Treatment of Cryptococcal Meningitis", 
        "overall_contact": {
            "email": "yeechunchen@gmail.com", 
            "last_name": "Yee-chun Chen, MD", 
            "phone": "886-2-2312-3456", 
            "phone_ext": "65054"
        }, 
        "overall_contact_backup": {
            "email": "d830166@cc.kmc.edu.tw", 
            "last_name": "Po-Liang Lu, MD", 
            "phone": "886-7-3121101", 
            "phone_ext": "5675"
        }, 
        "overall_official": {
            "affiliation": "National Taiwan University Hospital", 
            "last_name": "Yee-chun Chen, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Taiwan : Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Successful response was defined as both satisfactory clinical and microbiological  response at the completion of 14 days treatment period.", 
            "measure": "suscceful response rate", 
            "safety_issue": "No", 
            "time_frame": "Day 14"
        }, 
        "reference": {
            "PMID": "20047480", 
            "citation": "Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010 Feb 1;50(3):291-322. doi: 10.1086/649858."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02136030"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "TTY Biopharm", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "TTY Biopharm", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2010"
    }
}